Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Biomarker Identification, Viral Susceptibility and Management in S. aureus Colonized AD Patients

Award Number: U01AI152011
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/06/2020
PERIOD OF PERFORMANCE END DATE: 03/31/2027

Group Awards By:

View Award Description

Biomarker Identification, Viral Susceptibility and Management in S. aureus Colonized AD Patients - Project Summary/Abstract Staphylococcus aureus (S. aureus) has been strongly implicated as a causal factor in pathogenesis of atopic dermatitis (AD) since the 1970s, and is further supported by publications demonstrating S. aureus skin colonization precedes AD onset. ADRN studies found that 50% of AD subjects are colonized and this AD phenotype is associated with greater epidermal barrier dysfunction, type 2 immunity, disease severity and remarkable alterations in the skin microbiome (increased S. aureus relative abundance and reduced abundance of the commensal bacteria, Cutibacterium acnes (C. acnes). Additionally, S. aureus-colonized AD subjects are more likely to develop a severe viral condition, called eczema herpeticum. An even more serious condition is eczema vaccinatum, caused by exposure to vaccinia virus (smallpox vaccination), which has a fatality rate as high as 30%. In an effort to explain this, we found discovered that epidermal exposure to a highly virulent S. aureus strain (USA300), commonly found on AD subjects, markedly enhances its susceptibility to vaccinia virus. Collectively, these observations support our hypothesis that S. aureus may be a key driver of disease severity and response to systemic treatments (Aim 1) as well as serious viral complications (Aim 2). Determining what role C. acnes, the most abundant commensal skin bacteria, plays in suppressing S. aureus will be the focus of studies outlined in Aim 3. These studies will leverage the wealth of deeply-phenotyped AD subjects and their biospecimens from previous ADRN studies (ADRN02-Registry, ADRN06-ADEH and ADRN09-Dupilumab) and those enrolled into URMCs Longitudinal ‘Real-World’ AD Study. The Aims demonstrate how the focus is first on the systemic features of S. aureus colonization (e.g. macro level; Aim 1) and moves to the “epidermal (host) – microbiome” interaction (Aim 2) and ultimately to the microbe-microbe interaction at the skin surface (e.g. micro level; Aim 3).


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $462,039 )
2026	2026	UNIVERSITY OF ROCHESTER	910 GENESEE ST	ROCHESTER	NY	14611	MONROE	USA	Allergy and Infectious Diseases Research	001	7	4/10/2026	NON-COMPETING CONTINUATION	$462,039
2026	2025	UNIVERSITY OF ROCHESTER	910 GENESEE ST	ROCHESTER	NY	14611	MONROE	USA	Allergy and Infectious Diseases Research	000	6	3/20/2026	NON-COMPETING CONTINUATION	$0
														Subtotal = $462,039

Issue Date FY: 2025 ( Subtotal = $462,039 )
2025	2025	UNIVERSITY OF ROCHESTER	910 GENESEE ST	ROCHESTER	NY	14611	MONROE	USA	Allergy and Infectious Diseases Research	000	6	4/15/2025	NON-COMPETING CONTINUATION	$462,039
														Subtotal = $462,039

Issue Date FY: 2024 ( Subtotal = $462,039 )
2024	2024	UNIVERSITY OF ROCHESTER	910 GENESEE ST	ROCHESTER	NY	14611	MONROE	USA	Allergy and Infectious Diseases Research	000	5	3/15/2024	NON-COMPETING CONTINUATION	$462,039
														Subtotal = $462,039

Issue Date FY: 2023 ( Subtotal = $462,039 )
2023	2023	UNIVERSITY OF ROCHESTER	500 JOSEPH C WILSON BLVD	ROCHESTER	NY	14627	MONROE	USA	Allergy and Infectious Diseases Research	000	4	3/1/2023	NON-COMPETING CONTINUATION	$462,039
2023	2021	UNIVERSITY OF ROCHESTER	910 GENESEE ST	ROCHESTER	NY	14611	MONROE	USA	Allergy and Infectious Diseases Research	002	2	9/14/2023	NON-COMPETING CONTINUATION	$0
2023	2020	UNIVERSITY OF ROCHESTER	910 GENESEE ST	ROCHESTER	NY	14611	MONROE	USA	Allergy and Infectious Diseases Research	001	1	9/13/2023	NEW	$0
														Subtotal = $462,039

Issue Date FY: 2022 ( Subtotal = $462,039 )
2022	2022	UNIVERSITY OF ROCHESTER	500 JOSEPH C WILSON BLVD	ROCHESTER	NY	14627	MONROE	USA	Allergy and Infectious Diseases Research	001	3	5/4/2022	NON-COMPETING CONTINUATION	$462,039
2022	2021	UNIVERSITY OF ROCHESTER	500 JOSEPH C WILSON BLVD	ROCHESTER	NY	14627	MONROE	USA	Allergy and Infectious Diseases Research	000	2	3/2/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $462,039

Issue Date FY: 2021 ( Subtotal = $462,098 )
2021	2021	UNIVERSITY OF ROCHESTER	500 JOSEPH C WILSON BLVD	ROCHESTER	NY	14627	MONROE	USA	Allergy and Infectious Diseases Research	000	2	3/18/2021	NON-COMPETING CONTINUATION	$462,098
														Subtotal = $462,098

Issue Date FY: 2020 ( Subtotal = $475,598 )
2020	2020	UNIVERSITY OF ROCHESTER	500 JOSEPH C WILSON BLVD	ROCHESTER	NY	14627	MONROE	USA	Allergy and Infectious Diseases Research	000	1	4/6/2020	NEW	$475,598
														Subtotal = $475,598

Grand Total All Awards = $3,247,891

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Biomarker Identification, Viral Susceptibility and Management in S. aureus Colonized AD Patients

Award Number: U01AI152011

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/06/2020

PERIOD OF PERFORMANCE END DATE: 03/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer